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Abstract
The human APJ, a G protein-coupled seven-transmembrane receptor, has been found to be dramatically expressed in the human central
nervous system (CNS) and also to serve as a coreceptor for the entry of human immunodeficiency virus type 1 (HIV-1) and simian
immunodeficiency virus (SIV). Studies with animal models suggested that APJ and its natural ligand, apelin, play an important role in the
central control of body fluid homeostasis, and in regulation of blood pressure and cardiac contractility. In this study, we characterize the
structural and functional determinants of the N-terminal domain of APJ in interactions with its natural ligand and HIV-1 envelope
glycoprotein. We demonstrate that the second 10 residues of the N-terminal domain of APJ are critical for association with apelin, while
the first 20 amino acids play an important role in supporting cell–cell fusion mediated by HIV-1 gp120. With site-directed mutagenesis, we
have identified that the negatively charged amino acid residues Glu20 and Asp23 are involved in receptor and coreceptor functions, but
residues Tyr10 and Tyr11 substantially contribute to coreceptor function for both T-tropic (CXCR4) and dual-tropic (CXCR4 and CCR5)
HIV-1 isolates. Thus, this study provides potentially important information for further characterizing APJ-apelin functions in vitro and in
vivo and designing small molecules for treatment of HIV-1 infection in the CNS.
© 2003 Elsevier Inc. All rights reserved.
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Introduction
APJ, an orphan G protein-coupled, seven-transmem-
brane receptor, was originally identified from human
genomic DNA by O’Dowd et al. (1993) and later was also
isolated from mice (Devic et al., 1999) and rats (De Mota et
al., 2000; Hosoya et al., 2000; O’Carroll et al., 2000). The
human APJ gene encoding a 380 amino acid resembled the
angiotensin II receptor, sharing an identity of more than
30% in amino acid sequence, but angiotensin II was unable
to interact with APJ (O’Dowd et al., 1993; Tatemoto et al.,
1998). Recently the endogenous ligand for APJ receptor,
apelin, was first isolated from bovine stomach extracts
(Tatemoto et al., 1998), and the protein sequences of hu-
man, rat, and mouse apelin preproproteins were deduced
from the cDNAs (Tatemoto et al., 1998; Habata et al., 1999;
Hosoya et al., 2000; Lee et al., 2000).
Studies on the distribution of APJ and apelin demon-
strated that both were abundantly expressed in the central
nervous system (CNS) and periphery of human and rat
(O’Dowd et al., 1993; Matsumoto et al., 1996; Edinger et
al., 1998; Lee et al., 2000; Reaux et al., 2001, 2002). In
addition, significant similarities of sequence and tissue dis-
tributions between APJ/apelin and the AT1/angiotensin II
suggested that APJ and apelin would play an important
physiological role as a neurotransmitter or neuromodulator
(Lee et al., 2000; Reaux et al., 2001, 2002). In a rat model,
APJ/apelin has been shown to play an important role in the
hypothalamic regulation of water intake and the endocrine
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axes (Lee et al., 2000; Reaux et al., 2001; Taheri et al.,
2002), in regulation of blood pressure via a nitric oxide
-dependent mechanism (Lee et al., 2000; Tatemoto et al.,
2001), and cardiac contractility (Reaux et al., 2002; Szokodi
et al., 2002).
Recently the APJ receptor has been found to support
env-mediated membrane fusion or viral entry as an alterna-
tive coreceptor for human and simian immunodeficiency
viruses (HIV and SIV) (Choe et al., 1998; Edinger et al.,
1998; Zhang et al., 1998; Puffer et al., 2000). Consistently
apelin has been reported to be able to block the activity of
APJ as an HIV-1 coreceptor (Cayabyab et al., 2000; Puffer
et al., 2000; Zou et al., 2000). Although the absence of APJ
expression in microglia and macrophages, the principal
CD4-positive cell types in CNS, suggested initially that APJ
is unlikely to mediate HIV-1 infection in the CNS (Choe et
al., 2000), a recent study has shown that HIV-1 infection in
neural cells involves a chemokine-receptor-dependent but
CD4-independent entry (Alvarez Losada et al., 2002). In
addition, it was reported that some viral envelope proteins
could mediate fusion with APJ-positive, CD4-negative cells
(Puffer et al., 2000). With the detection of abundant expres-
sion of APJ in the CNS, these observations raise the possi-
bility that the APJ receptor might contribute to HIV-1 in-
fection and pathogenesis in the CNS.
Although many studies have investigated the physiolog-
ical role of APJ receptor, there is no report on the charac-
terization of the structure and function of APJ as a receptor
and a coreceptor. In the present study, we used deletion and
site-directed mutagenesis combined with binding and func-
tional assays to investigate structural determinants of APJ
for its ligand activation and coreceptor function. Our study
has revealed the residues in the N-terminal domain of APJ
critical for biological function and coreceptor activity and
provided information for further understanding the physio-
logical and pathological roles of APJ and elucidating mech-
anisms of HIV-1 viral entry.
Results
Effects of deletion of amino acids in the N-terminal
domain of APJ on functions of receptor and HIV-1
coreceptor activities
To evaluate the role of the N-terminal domain of APJ in
interaction with ligand and HIV-1 envelope protein gp120,
we constructed two APJ mutations, APJ10 with the deletion
of the first 10 amino acids in the N-terminal domain, and
APJ20 with a deletion of the first 20 amino acids (Fig. 1).
Both APJ10 and APJ20 were fused to the enhanced version
of the green fluorescent protein (EGFP) at its C-terminus for
easy and rapid detection of cell-surface expression and
receptor internalization. The cell-surface expression of APJ
mutants with deletion was evaluated by flow cytometry with
GFP and anti-human APJ monoclonal antibody. As shown
in Fig. 2A, FACS analysis with GFP indicated that deletion
of the first 10 and 20 amino acids in the N-terminal domain
resulted in about a 20 to 35% decrease in cell-surface
expression, but the expression of both APJ10 and APJ20 was
not detectable with monoclonal antibody (mAb)MAB856,
suggesting that mAb MAB856 recognizes the N-terminal
first 10 amino acids of APJ. APJ10 and APJ20 mutants were
further tested by binding and functional assay. The activities
of APJ10 in ligand binding, signaling, and internalization
remained comparable to wild-type, whereas deletion of 20
residues from the N-terminal domain resulted in complete
loss of binding activity and biological functions (Figs. 2B,
C, and D). We also examined the coreceptor activity using
a well-characterized luciferase-based cell fusion assay. The
results indicated that APJ10 and APJ20 exhibited lose of
60 and 80% of coreceptor activity, respectively, as
compared to wild-type APJ (Fig. 2E).
Cell-surface expression of APJ site-directed mutants
As shown in the APJ mutations with deletion of amino
acids in the N-terminal domain, the second 10 amino acids
of the N-terminus of APJ plays an important role in ligand
binding and function. To further identify amino acid side
chains that are essential for ligand binding and function, 11
residues located within the second 10 amino acids of the
N-terminal domain were selected for site-directed mutagen-
esis studies, and all of the selected residues were individu-
ally substituted with alanine (Fig. 1). All alanine-scanning
mutants were stably transfected into 293 cells, and cell-
surface expression was analyzed by flow cytometry with
both GFP and mAb MAB865. As illustrated in Fig. 3, the
mutant Y10A showed a higher expression level with detec-
tion of GFP, but similar expression levels to wild-type APJ
with mAb MAB865, while all other mutants exhibited ex-
pression levels comparable to wild-type APJ in detection by
both GFP and mAb MAB865.
Fig. 1. Amino acid sequence of the N-terminal domain of wild-type and
mutated APJ. Residues substituted with alanine are shown in bold. The
underlined sequence is the predicted transmembrane domain.
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Fig. 2. Expression and activities of APJ mutations with deletions. (A) Cell-surface expression of APJ mutants. 293 cells, stably transfected with wild-type
and mutant APJ, were analyzed with GFP and anti-APJ MAB856 by flow cytometry. (B) Binding activity. The 293 cells stably expressing wild-type and
mutant APJ were incubated with 125I-apelin-13 (0.2 nM) in the presence of 200 nM cold apelin-13, and cell-associated radioactivity was counted via gamma
emissions. The 293 cells were used as negative control. Error bars represent the standard error of the mean derived from three independent experiments. (C)
Receptor internalization. 293 cells stably expressing APJ-EGFP treated with apelin-36 (2 M) at 37°C for 40 min. (D) Intracellular Ca2 mobilization.
Intracellular Ca2 concentration in nontransduced 293 cells, or 293 cells stably expressing wild-type or mutant APJ, were measured in response to apelin-36
(3 M). The data shown are representative of at least three independent experiments. (E) Coreceptor activity of APJ. Target cells were cotransfected with
plasmids encoding coreceptors, CD4, and luciferase under the control of the T7 promoter. 293 effector cells were infected with a vaccinia virus encoding
T7 polymerase and a vaccinia virus encoding the specific HIV-1 IIIB envelope protein. Cell mixtures were maintained at 37°C for 4 to 6 h. Fusion was
determined by a luciferase assay. The target cells were cotransfected with APJ/CD4, but without CD4 as a negative control. Values are expressed as luciferase
activity (RLU/s). Error bars represent the standard error of the mean derived from three independent experiments.
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Ligand binding activities of alanine scanning mutants
In our previous study, 125I-apelin-13 was found to bind to
APJ receptor with high affinity (Zhou et al., 2002). In this
study, we used 125I-apelin-13 to examine our alanine-scan-
ning of APJ mutants for their ligand binding activity. As
shown in Fig. 4, replacement of Glu20 and Asp23 with
alanine resulted in a dramatic drop in ligand binding activ-
ity, and the E18A mutation exhibited a slight drop, whereas
mutant Y11A yielded an increase in binding activity.
Biological functions of alanine scanning mutants
APJ receptor undergoes rapid internalization upon expo-
sure to apelin (Reaux et al., 2001; Zhou et al., 2002, 2003).
We used an approach expressing an APJ–GFP fusion pro-
tein to visualize the receptor internalization for characteriz-
ing activation of mutated APJ by apelin ligand. After incu-
bation with 2 M apelin-13 or apelin-36 at 37°C for 40 min,
the stably expressing cells were observed using fluorescence
microscopy. Our analyses indicated that alanine substitution
of Asp23 led to complete loss of the potential for receptor
internalization induced by apelin (Fig. 5A). The E20A mu-
tant was found to be partially internalized from cell surface
upon exposure to apelin. Other mutations showed no effects
on receptor internalization in response to ligand.
To evaluate the effects of alanine substitution in the
N-terminal domain of APJ on signal transduction in re-
sponse to apelin, changes in intracellular Ca2 were moni-
tored. The results are illustrated in Fig. 5B. Consistent with
binding activity and receptor internalization, the D23A mu-
tant showed no response in intracellular Ca2 upon stimu-
lation with 3 M apelin, and E20A exhibited a low-intensity
Ca2 alteration.
Coreceptor activities of APJ site-directed mutations
To further examine the role of APJ as a coreceptor to
mediate HIV-1 infection, in preliminary experiments, hu-
man HEK-293 cells expressing CD4 and APJ were infected
with the HIV-1 89.6 isolate, and the efficiency of infection
was determined by detection of HIV-1 p24 antigen 3 days
after infection. The results, in Fig. 6A, showed that the 293
cells expressing CD4 and APJ could be infected by HIV-1
89.6, and the infection by 89.6 viruses was inhibited in a
dose-dependent manner by the synthetic ligand apelin-36,
but not by SDF-1, the ligand of human CXCR4.
The alanine scanning APJ mutants were further exam-
ined for their ability to support HIV-1 entry as a coreceptor
using a well-characterized cell-fusion reporter assay. QT6
target cells were cotransfected with plasmid vectors ex-
pressing wild-type APJ or APJ mutants, CD4, and luciferase
under the control of T7 promoter. 293 effector cells were
coinfected with vaccinia viruses encoding HIV-1 envelope
proteins and T7 RNA polymerase, respectively. After 5 h of
fusion, cells were lysed and quantitatively analyzed by
Fig. 3. Cell-surface expression of alanine-scanning APJ mutants. 293 cells, stably transfected with wild-type and alanine-scanning mutated APJ, were
analyzed with GFP (A) and anti-APJ MAB856 (B) by flow cytometry. Experiments were repeated at least three times, and results are expressed as the mean
value  SE.
Fig. 4. Binding activity of alanine-scanning APJ mutants. The APJ stably
expressing 293 cells were incubated with 125I-apelin-13 (0.2 nM) in the
presence of 200 nM cold apelin-13, and cell-associated radioactivity was
counted by gamma emissions. The bars represent the mean values of three
independent assays, whereas the error bars are the mean  SEM.
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luciferase assay. The results are shown in Fig. 6B and
presented as an average of the percentages of wild-type
APJ. Replacement of Tyr10, Tyr11, and Asp23 with alanine
resulted in a dramatic decrease (80%) in coreceptor ac-
tivity for both the T-tropic (X4) IIIB and the dual-tropic
(R5X4) 89.6. Relatively lower reductions (50%) in po-
tency toward inducing cell–cell fusion mediated by T-tropic
IIIB gp120, but not by dual-tropic 89.6 gp120, were ob-
served when Asp14, Glu18, Glu20, and Trp24 were indi-
vidually substituted with alanine.
For further confirmation of coreceptor activity, Y10A,
Y11A, Y21A, and D23A mutants were tested at the same
time for coreceptor activity and transient cell-surface ex-
pression. As shown in Fig. 6C and D, although the cell-
surface expression of APJ mutants in transiently transfected
QT6 cells was comparable to wild-type, Y10A, Y11A, and
D23A mutants showed a significant decrease in the ability
to support cell–cell fusion.
Discussion
APJ and its natural ligand apelin were found to distribute
in the CNS and periphery of the human and rat (O’Dowd et
al., 1993; Matsumoto et al., 1996; Edinger et al., 1998; Lee
et al., 2000; Reaux et al., 2001, 2002). Recent studies
suggested that APJ plays an important physiological role
(Lee et al., 2000; Tatemoto et al., 2001; Reaux et al., 2001,
2002; Szokodi et al., 2002; Taheri et al., 2002). In addition,
APJ receptor has been found to support env-mediated mem-
brane fusion or viral entry as a coreceptor for HIV and SIV
(Choe et al., 1998; Edinger et al., 1998; Zhang et al., 1998;
Puffer et al., 2000). The characterization of structural and
functional determinants of APJ for its ligand activation and
coreceptor function is essential toward better understanding
the physiological and pathological roles of APJ and eluci-
dating mechanisms of HIV-1 viral entry plus developing
novel anti-HIV-1 agents. In this study, we used deletion and
site-directed mutagenesis combined with binding and func-
tion assays to investigate the role of the N-terminal domain
of APJ in ligand activation and coreceptor function.
Our previous study had demonstrated that fusing APJ
with the enhanced version of the EGFP at the C-terminus
maintained its full biological activities in binding, signaling,
and HIV-1 gp 120-induced cell membrane fusion (Zhou et
al., 2002). This is in agreement with observations in
CCKAR (Tarasova et al., 1997), the 2-adrenergic receptor
(Barak et al., 1997), and CXCR4 (Tarasova et al., 1998). In
the present study, we used GFP-fused expression of wild-
type and mutant APJs for efficiently detecting cell-surface
expression and receptor internalization. By FACS analysis
with GFP and monoclonal antibody MAB856, the results
Fig. 5. Biological functions of alanine-scanning APJ mutations. (A) Induction of receptor internalization by apelin-36 peptides. 293 cells stably expressing
wild type and mutated APJ treated with 2 M apelin-36 at 37°C for 40 min. (B) Induction of intracellular Ca2 mobilization. Intracellular Ca2 concentration
in 293 cells stably expressing wild-type and mutated APJ was measured in response to 3 M apelin-36. The data shown are representative of three
independent experiments.
88 N. Zhou et al. / Virology 317 (2003) 84–94
showed no difference in cell-surface expression of wild-
type and mutated APJ. In addition, observation with fluo-
rescence microscopy demonstrated that the GFP-fused wild-
type APJ and APJ mutants were mainly distributed evenly
along the cell membrane. Our results also showed that
alanine substitution of Asp23 resulted in substantial loss of
binding activity, signaling, and receptor internalization, in-
dicating that receptor internalization was well-correlated
with binding activity and intracellular Ca2 mobilization.
The assay of receptor internalization was a sensitive, sim-
ple, and useful means to characterize G-protein coupled
receptors (GPCR).
Previous studies have demonstrated that the N-terminal
domain plays a critical role in the ability of ligands to
associate with G-protein coupled chemotactic receptors:
Duffy antigen, a receptor that binds to both CC and CXC
chemokines (Lu et al., 1995), IL-8 receptor (He`bert et al.,
1993; Horuk, 1994; Ahuja et al., 1996), C5a receptor (Far-
zan et al., 2001), CCR2b (Preobrazhensky et al., 2000),
CCR5 (Zhou et al., 2000), and CXCR4 (Doranz et al., 1999;
Zhou et al., 2001). In this study, the second 10 residues
within the N-terminal domain of the APJ receptor were
found to be essential for interaction with its ligand. Further-
more, the alanine substitution of residues Asp23 and Glu20
impaired ligand binding activity and key biological func-
tions, suggesting the negatively charged residues in the
N-terminal domain are critical for the APJ receptor to in-
teract with apelin. Cayabyab et al. (2000) have reported that
the positively charged arginine residues at positions of 63
and 64 in the apelin-15 peptide play an important role for
the specific ability to block HIV-1 entry via the APJ core-
ceptor. Our previous study (Zhou et al., 2002) showed that
substitution of alanine at sites R66, R68, and K72 resulted
in decreased receptor binding and internalization (and un-
Fig. 6. Coreceptor activity of alanine-scanning mutated APJ. (A) HIV-1 cell-free virus infection assay. The human 293 cells expressing CD4 and APJ were
incubated with apelin-36 (M) and SDF-1 (nM) for 15 min prior to addition of 10 ng of p24 of HIV-1 89.6 viruses. The HIV-1 p24 antigen levels were
measured 72 h after infection, using enzyme-linked immunosorbent assays. Similar results were obtained in additional independent experiments. (B)
Coreceptor activity of alanine scanning mutant APJ receptors in mediating cell–cell fusion by the T-tropic IIIB and dual-tropic 89.6 gp120s is illustrated.
Target cells were cotransfected with plasmids encoding wild-type APJ or APJ mutants, CD4, and luciferase under the control of the T7 promoter. 293 effector
cells were infected with a vaccinia virus encoding the T7 polymerase and a vaccinia virus encoding a strain-specific HIV-1 envelope protein. Cell mixtures
were maintained at 37°C for 4 to 6 h. Fusion was determined by a luciferase assay. The target cells were cotransfected with APJ/CD4, and without APJ as
negative control. The values were normalized by setting the extent of luciferase activity obtained when CD4 and wild-type APJ were coexpressed at 100%.
All experiments were repeated at least three times, and results are expressed as the mean value  SEM. (C) Coreceptor activities of APJ mutants and (D)
cell–surface expression of APJ mutants were determined in the same transient transfection, by cell–cell fusion assay with HIV-1 89.6 gp120 and FACS
analysis with GFP and MAB856. All experiments were repeated at least three times, and results are expressed as the mean value  SEM.
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published data). It is noteworthy that the net charge of the
N-terminal domain of APJ is 7. We hypothesized that the
negatively charged N-terminal domain of APJ is critical for
forming favorable electrostatic interactions with the posi-
tively charged residues in apelin.
HIV-1 infection of human cells requires the receptor
CD4 and chemokine receptors as coreceptors. The major
coreceptors used by HIV-1 viruses are CCR5 and CXCR4
(Deng et al., 1996; Doranz et al., 1996; Dragic et al., 1996;
Feng et al., 1996). Recently, the APJ receptor has been
identified as an alternative coreceptor for HIV-1 and SIV to
support env-mediated membrane fusion or viral entry in
vitro (Choe et al., 1998; Edinger et al., 1998; Zhang et al.,
1998; Puffer et al., 2000). In our preliminary infection
assay, the human 293 cells expressing CD4 and APJ were
infected with HIV-1 89.6 viruses, and the infection of 89.6
virues could be inhibited by apelin-36, the natural ligand of
APJ, by not by SDF-1, ligand of CXCR4, suggesting that
APJ receptor functioned as a coreceptor of HIV-1. Although
some reports argue for the significance of APJ as a core-
ceptor during in vivo infection with HIV-1 (Choe et al.,
2000; Puffer et al., 2000), identification of structural deter-
minants of APJ in mediation of HIV-1 entry is helpful for
fuller understanding of the interactions of HIV-1 env gly-
coprotein with CD4 and coreceptor toward developing
novel anti-HIV-1 agents.
In the present study, we use a well-characterized cell–
cell fusion assay to evaluate the coreceptor activities of APJ
mutations. The data showed that deletion of the first 10
residues and 20 residues in the N-terminal domain resulted
in 60 and 80% reduction of coreceptor activity, respectively,
indicating that the N-terminal domain was required for
interactions with HIV-1 gp120. Further site-directed mu-
tagenesis analysis demonstrated that residues Tyr10, Tyr11,
and Asp23 were critical in supporting env glycoprotein-
mediated membrane fusion for both T-tropic and dual-tropic
viruses. It was interesting to note that replacement of neg-
atively charged residues Asp20, Glu18, and Glu20 with
alanine impaired cell–cell fusion activity mediated by T-
tropic viral env glycoprotein. APJ has a negatively charged
N-terminal domain, similar to CXCR4. Mutagenesis studies
also indicated that the negatively charged residues in the
N-terminal domain were critical determinants for CXCR4
coreceptor activity (Chabot et al., 1999; Brelot et al., 2000).
In addition, the V3 loop of gp120 from T-tropic isolates has
been found to have a higher net positive charge than the V3
loop from M-tropic strains (O’Brien et al., 1996). It is likely
that the electrostatic interactions of coreceptors with HIV-1
gp120 play significant roles in CXCR4 and APJ coordinated
cell entry by T-tropic viruses. Our previous study demon-
strated that ALX40-4C, initially identified as a small-mol-
ecule antagonist of the chemokine receptor CXCR4, di-
rectly bound to APJ and prevented use of APJ as a HIV-1
coreceptor (Zhou et al., 2003). Taken together, APJ as a
receptor and coreceptor, in structure and function, bears a
strong resemblance to CXCR4, although APJ contains an
aminoterminal NYYG sequence, and a similar motif,
NYYT, has been identified at the N-terminal domain of
CCR5, that is particularly important for coreceptor function
(Farzan et al., 1998).
There are three tyrosine residues, Tyr10, Tyr11, and
Tyr21, within the N-terminal domain of APJ. The same
tyrosine-rich N-terminal domain exists in most or all che-
mokine receptors and all HIV-1 coreceptors (Farzan et al.,
1999). CCR5 contains at least three sulfated tyrosines
within the N-terminal domain that contribute to both recep-
tor functions and coreceptor activity (Farzan et al., 1999;
Bannert et al., 2001). The tyrosine sulfate moieties on
CCR2b and the chemotactic receptor for C5a also have been
observed to play an important role in association with ligand
(Bannert et al., 2001; Farzan et al., 2001). In the case of
CXCR4, the sulfate group at tyrosine 21 makes a substantial
contribution to its interaction with ligand SDF-1, but plays
a less significant role in CXCR4-mediated HIV-1 entry than
in CCR5-dependent HIV-1 entry (Farzan et al., 2002). How-
ever, in the present study, we observed that Tyr10 and
Tyr11 of APJ receptor were critical for the ability to support
cell–cell fusion mediated by both T-tropic and dual-tropic
HIV-1 isolates, but none of the three tyrosine residues
contributed to receptor binding and function. We observed
that the deletion mutant APJ10 still showed some activity,
although quite less, in support of IIIB gp120 induced cell–
cell fusion. Nonetheless, the site-directed mutant Y10A
maintained little coreceptor activity for both 89.6 and IIIB
gp120. This discrepancy may be accounted for by the con-
formational change induced by alanine substitution at
Tyr10.
We have characterized the role of the N-terminal domain
of APJ receptor in association with ligand and HIV-1 env
glycoprotein. Our results have revealed the residues in the
N-terminal domain of APJ critical for biological function
and coreceptor activity. In the case of most G-protein cou-
pled receptors, the N-terminal domain, together with two or
three extracellular loops, are involved in interactions with
ligand, and also with HIV-1 envelope glycoproteins. How-
ever, further studies are necessary to examine the role of the
extracellular loops of APJ in ligand binding functions and
coreceptor activity.
Materials and methods
Materials
Dulbecco’s modified Eagle’s medium (DMEM), fetal
bovine serum, and G418 were purchased from Life Tech-
nologies, Inc. Rhodamine red concanavalin A (ConA), tet-
ramethylrhodamine-transferrin, LysoTracker Red, furo-2,
and Pluronic F-127 were purchased from Molecular Probes
Inc. (Eugene, OR). Anti-human APJ monoclonal antibody
(MAB856) was obtained from R&D Systems, Inc. Plasmid
pCDNA-APJ, recombinant vaccinia viruses encoding two
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envelopes of HIV-1 vSC60 (IIIB) and vBD3 (89.6), and
vTF1.1 encoding T7 RNA polymerase were generous gifts
from Dr. Robert W. Doms, University of Pennsylvania. The
vector pEGFP-N1 was purchased from Clontech Laborato-
ries, Inc. (Palo Alto, CA).
Cell and cell culture
The HEK-293 cell line was obtained from the AIDS
Research and Reference Reagent Program (Division of
AIDS, NIAID, NIH). The Japanese quail fibrosarcoma QT6
cell line was kindly provided by Robert W. Doms (Univer-
sity of Pennsylvania, Philadelphia, PA). HEK-293 and QT6
cells were maintained in DMEM plus 10% fetal bovine
serum.
DNA construction and mutagenesis
Plasmid pCDNA-APJ containing the human APJ gene
was kindly provided by Robert W. Doms (University of
Pennsylvania, Philadelphia, PA). The full open reading
frame (ORF) of wild-type and N-terminally deleted APJ
were amplified using polymerase chain reaction (PCR) and
subcloned in-frame into HindIII and BamHI sites of the
pEGFP-N1 vector. All constructs were sequenced to con-
firm the correct sequence and orientation.
Site-directed mutagenesis was performed on pAPJ-
EGFP vector and prepared with QuikChange Site-Directed
Mutagenesis Kit (Stratagene, La Jolla, CA), according to the
manufacturer’s instructions. The mutations were confirmed
by sequencing. The plasmid constructs of wild-type APJ
and mutants were transfected into 293 cells by the calcium-
phosphate precipitation method. Twenty-four hours after
transfection, selection for stable expression was initiated by
the addition of G418 (800 g/ml). Transfected cells were
evaluated for expression levels at the cell surface by flow
cytometry.
Radioligand binding assay
The radioiodinated human apelin-13 was purchased from
Amersham Biosciences, Inc. (Piscataway, NJ). The specific
activity of human 125I-apelin-13 was 2000 Ci/mmol. The
binding assay was carried out as described previously (Zhou
et al., 2002). The wild-type APJ and mutated APJ stably
expressing 293 cells were harvested in phosphate-buffered
saline (PBS) (Ca2 and Mg2 free) plus 0.5 mM EDTA and
washed twice with PBS. Ligand binding experiments were
performed using a single concentration (0.2 nM) of 125I-
apelin-13 in the absence or presence of 200 nM cold ape-
lin-13 in a final volume of 100 l of binding buffer (50 nM
HEPES pH 7.4, 1 nM CaCl2, 5 nM MgCl2, 0.1% bovine
serum albumin) containing 5  105 cells. Samples were
incubated for 60 min at room temperature. The incubation
was terminated by separating the cells from the binding
buffer by centrifugation and washing once with 500 l of
cold binding buffer. Bound ligands were determined by
counting gamma emissions. At least three independent ex-
periments were performed.
Flow cytometry
APJ-EGFP and APJ mutant stably transfected 293 cells
(2  105) were washed with fluorescence-activated cell
sorting (FACS) buffer (0.3% bovine serum albumin, 0.05%
sodium azide in PBS) and fixed in fixing buffer (2% para-
formaldehyde in PBS). For detection of APJ expression
using anti-APJ antibody, stably or transiently APJ express-
ing cells were harvested with PBS containing 5 mM EDTA.
After washing with FACS buffer, cells were incubated with
an anti-APJ mAb (10 g/ml) for 30 min at 4°C. After
washing with FACS buffer, cells were incubated with 10
g/ml PE-conjugated goat anti-mouse IgG (PharMingen)
for 30 min at 4°C. After washing twice with FACS buffer,
cells were fixed in fixing buffer (2% paraformaldehyde in
PBS) and then analyzed on a FACScan flow cytometer
(Coulter EPICS Elite, Coolten Corp., Hialeah, FL).
Receptor internalization and fluorescence microscopy
The stable APJ or mutated APJ expressing 293 cells
were seeded on Nunc two-chamber slides and incubated at
37°C overnight. After treatment with apelin at 37°C for 40
min, cells were washed in PBS and then fixed in PBS
containing 2% paraformaldehyde for 10 min. Fluorescence
microscopy was performed on an Olympus System micro-
scope, model BX60, with fluorescence attachment BX-
FLA.
Intracellular calcium measurements
Intracellular Ca2 was monitored following a modified
procedure, as published by others (Donnadieu et al., 1994;
Heveker et al., 1998). Briefly, untransduced 293 cells and
wild-type APJ or APJ mutant stably transfected 293 cells
were cultured in the DMEM medium containing 10% FBS.
Cells were harvested with PBS containing 5 mM EDTA and
washed twice with PBS. For Ca2 mobilization studies, 5
106/ml cells were loaded with the fluorescent dye, fura-2 (3
M), and 0.05% F172, in Hank’s balanced salt solution
(140 mM NaCl, 5 mM KCl, 10 mM HEPES pH 7.4, 1 mM
CaCl2, 1 mM MgCl2, 1 mg/ml glucose, and 0.025% BSA),
for 30 min at 37°C. The cells were washed three times and
resuspended at a concentration of 30 to 40  106/ml, then
1.5 to 2  106 cells were tested in the same buffer. Intra-
cellular Ca2 mobilization was measured using excitation at
340 and 380 nm in a fluorescence spectrometer (Perkin–
Elmer LS50B, Beaconsfield, UK), upon stimulation with
apelin. Intracellular Ca2 concentrations were calculated
using a fluorescence spectrometer measurement program.
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HIV-1 infection assay
To determine coreceptor activity of APJ receptor in me-
diating HIV-1 infection, the human HEK-293 cells were
transfected with CD4 and APJ. The 293 cells expressing
CD4/APJ were challenged with 10 ng of HIV-1 p24 antigen,
isolate 89.6, for 6 h, and then washed three times. For
inhibition with ligand, the cells were incubated with indi-
cated amounts of apelin-36 and SDF-1 for 15 min prior to
addition of HIV-1. Supernatants were collect for p24 anti-
gen measurement by ELISA, 72 h after infection. The
HIV-1 p24 antigen levels were measured using enzyme-
linked immunosorbent assays (ELISA; Zeptometrix).
Gene reporter fusion assay
A gene reporter fusion assay was used to determine the
coreceptor activity of APJ in mediating HIV-1 viral entry
following a modified procedure, as published by others
(Nussbaum et al., 1994; Doranz et al., 1996; Rucker et al.,
1997). Briefly, the effector 293 cells were infected with
recombinant vaccinia virus with diverse HIV-1 Env proteins
and T7 RNA polymerase for 2 h. Infected cells were then
trypsinized, washed with PBS, resuspended in medium, and
incubated overnight at 32°C in the presence of rifampicin
(100 g/ml). Target QT6 cells were cotransfected in six-
well plates with plasmids encoding CD4, wild-type, or mu-
tant APJs and luciferase under control of the T7 promotor,
using the calcium-phosphate precipitation method. Four
hours after transfection, cells were lifted, seeded in 24-well
plates, and incubated at 37°C overnight. To initiate fusion,
105 effector cells were added to each well and incubated at
37°C. After 5 h of fusion, cells were lysed in 100 l of
reporter lysis buffer (Pharmingen) and assayed for lucif-
erase activity by using commercially available reagents
(Pharmingen) with FB12 Luminometer (Zylux Corp.,
Maryville, TN).
Peptide synthesis
Peptide synthesis was carried out as described previously
(Zhou et al., 2002). Briefly, apelin-13 and apelin-36 were
prepared by solid-phase synthesis using Fmoc-strategy on a
430A peptide synthesizer (Applied Biosystems, Foster City,
CA) and a 9050 Pepsynthesizer Plus (Perceptive Biosys-
tems, Cambridge, MA). Crude peptides were purified by
preparative reverse-phase high-performance liquid chroma-
tography using a Dynamax-300 Å C18 25 cm 21.4 mm ID
column with flow rate of 9 ml/min and two solvent systems
of 0.1% TFA/H2O and 0.1% TFA/acetonitrile. Fractions
containing the appropriate peptide were pooled together and
lyophilized. The purity of the final product was assessed by
analytical reverse-phase high-performance liquid chroma-
tography, capillary electrophoresis, and matrix-assisted la-
ser desorption/ionization time-of-flight mass spectrometry.
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